Drug news

SOBI will sell Orfadin in US,Canada and Latin America

Read time: 1 mins

Last updated:22nd Dec 2013

Published:22nd Dec 2013

Source: Pharmawand

Swedish Orphan Biovitrum AB (Sobi) announced that the company has decided to take direct responsibility for Orfadin in the US, Canada, and Latin America by terminating the current distributorship agreement with their partner Rare Disease Therapeutics, Inc.,

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Sage Therapeutics and Biogen announce SAGE 324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor

Sage Therapeutics, Inc. and Biogen Inc. announced topline results from the Phase II KINETIC 2 dose-range study of the oral investigational drug SAGE 324 (BIIB124) as a potential treatment in essential tremor (ET)

1 mins

Drug news

Positive topline results from phase III study of giroctocogene fitelparvovec a hemophilia A gene therapy candidate

Pfizer Inc. announced positive topline results from the Phase III AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A.

3 min

Drug news

MHRA (UK) approves first-in-class Truqap (capivasertib), in combination with fulvestrant, for treating the most common type of advanced breast cancer.-AstraZeneca

The Medicines & Healthcare products Regulatory Agency (MHRA) has approved a first-in-class drug, capivasertib (Truqap), in combination with fulvestrant, for treating the most common type of advanced breast cancer

1 min

See all news